Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.02.003
Anne-Marie Neumann, Cathleen Geißler, Randy Seeley, Henriette Kirchner, Henrik Oster
Bariatric surgery is an effective intervention to treat excess weight and deteriorated metabolic health. A majority of patients further benefit from improvements of mental health and the psychosocial state. However, given the complex interplay of factors affecting sociability in humans, the corresponding effects of the surgery remain unclear. In this study, we investigated the effects of vertical sleeve gastrectomy (VSG) on sociability and social interaction in male, obese mice. Results showed an increase in time spent in the social chamber 9 and 30-35 days post-surgery as well as increased interaction with a subject at 9 days post-surgery. The initial enhancement in social behavior was associated with rapid weight loss, but long-term effects persisted beyond this phase when weight was largely recovered. The findings suggest that VSG positively influences sociability, potentially through mechanisms involving the HPA axis, as previously reported. This study provides new insights into the psychosocial benefits of bariatric surgery.
{"title":"Vertical sleeve gastrectomy improves social behaviors in obese, male mice","authors":"Anne-Marie Neumann, Cathleen Geißler, Randy Seeley, Henriette Kirchner, Henrik Oster","doi":"10.1016/j.orcp.2025.02.003","DOIUrl":"10.1016/j.orcp.2025.02.003","url":null,"abstract":"<div><div>Bariatric surgery is an effective intervention to treat excess weight and deteriorated metabolic health. A majority of patients further benefit from improvements of mental health and the psychosocial state. However, given the complex interplay of factors affecting sociability in humans, the corresponding effects of the surgery remain unclear. In this study, we investigated the effects of vertical sleeve gastrectomy (VSG) on sociability and social interaction in male, obese mice. Results showed an increase in time spent in the social chamber 9 and 30-35 days post-surgery as well as increased interaction with a subject at 9 days post-surgery. The initial enhancement in social behavior was associated with rapid weight loss, but long-term effects persisted beyond this phase when weight was largely recovered. The findings suggest that VSG positively influences sociability, potentially through mechanisms involving the HPA axis, as previously reported. This study provides new insights into the psychosocial benefits of bariatric surgery.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 80-83"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To investigate the effect of visualizing blood glucose variability by intermittently scanned continuous glucose monitoring (isCGM) on weight reduction in overweight individuals with impaired glucose tolerance (IGT) or mild type 2 diabetes mellitus (T2DM).
Materials and methods
Forty overweight (BMI, ≥25 kg/m2) individuals with IGT or T2DM (drug naïve; HbA1c, ≤7.0 %) were included in this 24-week randomized controlled trial. Participants were randomly assigned to the control group (diet and exercise therapy) or the isCGM group (diet and exercise therapy plus isCGM). The primary endpoint was the change in body weight during the 24-week intervention period.
Results
One participant in the isCGM group withdrew consent. We therefore analyzed 19 individuals in the isCGM group and 20 in the control group. Baseline BMI was significantly higher in the isCGM group (35.2 ± 5.7 kg/m²) compared to the control group (31.6 ± 6.8 kg/m²). Weight change in the isCGM and control groups (–1.8 and –2.2 kg) did not differ. However, the change in coefficient of variation (–0.9 and 2.9 %) of sensor glucose differed significantly between the two groups. isCGM scan frequency was positively correlated with time above range (TAR) during the first month, positively correlated with the change in protein intake, and negatively correlated with that in TAR.
Conclusion
While isCGM use in overweight individuals with IGT or mild T2DM did not reduce body weight, it might have influence dietary behavior. The negative correlation between scan frequency and TAR, and the positive correlation between scan frequency and protein intake suggest that self-awareness of glucose fluctuations contributed to behavioral change.
{"title":"Effects of intermittently scanned continuous glucose monitoring on body weight and glycemic variability in individuals with overweight and impaired glucose tolerance or mild diabetes: A pilot randomized controlled trial","authors":"Seiji Nishikage , Yasushi Nakagawa , Yushi Hirota , Kai Yoshimura , Mariko Ueda , Akane Yamamoto , Tomofumi Takayoshi , Atsuko Matsuoka , Michiko Takahashi , Akihiko Takeda , Kazuki Yokota , Tomoaki Nakamura , Kazuhiko Sakaguchi , Wataru Ogawa","doi":"10.1016/j.orcp.2025.01.008","DOIUrl":"10.1016/j.orcp.2025.01.008","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the effect of visualizing blood glucose variability by intermittently scanned continuous glucose monitoring (isCGM) on weight reduction in overweight individuals with impaired glucose tolerance (IGT) or mild type 2 diabetes mellitus (T2DM).</div></div><div><h3>Materials and methods</h3><div>Forty overweight (BMI, ≥25 kg/m2) individuals with IGT or T2DM (drug naïve; HbA1c, ≤7.0 %) were included in this 24-week randomized controlled trial. Participants were randomly assigned to the control group (diet and exercise therapy) or the isCGM group (diet and exercise therapy plus isCGM). The primary endpoint was the change in body weight during the 24-week intervention period.</div></div><div><h3>Results</h3><div>One participant in the isCGM group withdrew consent. We therefore analyzed 19 individuals in the isCGM group and 20 in the control group. Baseline BMI was significantly higher in the isCGM group (35.2 ± 5.7 kg/m²) compared to the control group (31.6 ± 6.8 kg/m²). Weight change in the isCGM and control groups (–1.8 and –2.2 kg) did not differ. However, the change in coefficient of variation (–0.9 and 2.9 %) of sensor glucose differed significantly between the two groups. isCGM scan frequency was positively correlated with time above range (TAR) during the first month, positively correlated with the change in protein intake, and negatively correlated with that in TAR.</div></div><div><h3>Conclusion</h3><div>While isCGM use in overweight individuals with IGT or mild T2DM did not reduce body weight, it might have influence dietary behavior. The negative correlation between scan frequency and TAR, and the positive correlation between scan frequency and protein intake suggest that self-awareness of glucose fluctuations contributed to behavioral change.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 70-76"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.02.002
Hye-Ji An , Sarah Woo , Hyun Jung Lim , Yoon Myung Kim , Kyung Hee Park
Objective
This observational study investigated the association between food addiction (FA) and emotional and behavioral problems in children and adolescents with obesity.
Method
This study enrolled 224 children and adolescents with body mass index (BMI) above the 85th percentile (mean age: 11.37). Along with anthropometric measurements, various psychosocial characteristics such as the Youth Self Report (YSR), self-esteem scale, and family function were investigated through questionnaires. Using the Yale Food Addiction Scale for Children (YFAS-C), all participants were divided into the FA and non-FA groups.
Results
The FA group had a higher BMI z-score, lower self-esteem scale score, and lower family function than the non-FA group. The FA group showed significantly higher YSR subscale T-scores, including total problems, internalization, and externalization, and a higher proportion of participants in the borderline and clinical group on the YSR total problems and problem behavior syndrome scales. Linear regression analysis showed that the YFAS-C symptom count score was independently associated with higher total YSR problems (β=0.036, 95 % CI [0.014, 0.059]) and externalizing t-scores (β=0.042, 95 % CI [0.020, 0.064]), and tended to be associated with internalizing t-scores (β=0.021, 95 % CI [-0.0004, 0.042]).
Conclusions
FA was significantly associated with emotional and behavioral problems in children and adolescents with obesity. Therefore, understanding FA in children and adolescents is important for the prevention and treatment of obesity and psychosocial difficulties.
{"title":"Emotional and behavioral problems associated with food addiction in children and adolescents with obesity","authors":"Hye-Ji An , Sarah Woo , Hyun Jung Lim , Yoon Myung Kim , Kyung Hee Park","doi":"10.1016/j.orcp.2025.02.002","DOIUrl":"10.1016/j.orcp.2025.02.002","url":null,"abstract":"<div><h3>Objective</h3><div>This observational study investigated the association between food addiction (FA) and emotional and behavioral problems in children and adolescents with obesity.</div></div><div><h3>Method</h3><div>This study enrolled 224 children and adolescents with body mass index (BMI) above the 85th percentile (mean age: 11.37). Along with anthropometric measurements, various psychosocial characteristics such as the Youth Self Report (YSR), self-esteem scale, and family function were investigated through questionnaires. Using the Yale Food Addiction Scale for Children (YFAS-C), all participants were divided into the FA and non-FA groups.</div></div><div><h3>Results</h3><div>The FA group had a higher BMI z-score, lower self-esteem scale score, and lower family function than the non-FA group. The FA group showed significantly higher YSR subscale T-scores, including total problems, internalization, and externalization, and a higher proportion of participants in the borderline and clinical group on the YSR total problems and problem behavior syndrome scales. Linear regression analysis showed that the YFAS-C symptom count score was independently associated with higher total YSR problems (β=0.036, 95 % CI [0.014, 0.059]) and externalizing t-scores (β=0.042, 95 % CI [0.020, 0.064]), and tended to be associated with internalizing t-scores (β=0.021, 95 % CI [-0.0004, 0.042]).</div></div><div><h3>Conclusions</h3><div>FA was significantly associated with emotional and behavioral problems in children and adolescents with obesity. Therefore, understanding FA in children and adolescents is important for the prevention and treatment of obesity and psychosocial difficulties.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 34-42"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.01.009
Pedro Henrique Siedschlag Schmidt , Eric Pasqualotto , Henrique Vilar dos Santos , Lis Sodré Nonato de Souza , Bruno Eulálio dos Santos , Matheus Pedrotti Chavez , Rafael Oliva Morgado Ferreira , Alexandre Hohl , Marcelo Fernando Ronsoni , Simone van de Sande-Lee
Aim
To evaluate the effect of liraglutide on body composition in people living with obesity or overweight.
Methods
A systematic search was conducted in PubMed, Embase, and Cochrane Library databases up to June 10, 2024. Randomized controlled trials (RCTs) comparing liraglutide to placebo and reporting body composition outcomes were included.
Results
Data from 15 studies involving 960 participants were analyzed. Liraglutide consistently demonstrated significant reductions in total weight, fat mass, and visceral adipose tissue (VAT) compared to placebo across the included studies. VAT reductions ranged from 12.49 % to 23 %, highlighting liraglutide's effectiveness in targeting visceral fat, a key factor in cardiometabolic risk. Fat mass reductions were also substantial and consistent, reinforcing the efficacy of liraglutide in improving overall body composition. In contrast, lean mass outcomes were more variable, with some studies reporting preservation or even gains in lean mass, while others indicated losses.
Conclusions
Liraglutide effectively reduces fat mass and VAT, supporting its use in managing obesity and related cardiometabolic risks. However, the inability to accurately calculate lean and fat mass proportions underscores the need for standardized reporting and availability of individual-level data. Future research should prioritize these elements and include muscle function assessments to better evaluate the clinical impacts of GLP-1 receptor agonists on body composition.
{"title":"Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review","authors":"Pedro Henrique Siedschlag Schmidt , Eric Pasqualotto , Henrique Vilar dos Santos , Lis Sodré Nonato de Souza , Bruno Eulálio dos Santos , Matheus Pedrotti Chavez , Rafael Oliva Morgado Ferreira , Alexandre Hohl , Marcelo Fernando Ronsoni , Simone van de Sande-Lee","doi":"10.1016/j.orcp.2025.01.009","DOIUrl":"10.1016/j.orcp.2025.01.009","url":null,"abstract":"<div><h3>Aim</h3><div>To evaluate the effect of liraglutide on body composition in people living with obesity or overweight.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in PubMed, Embase, and Cochrane Library databases up to June 10, 2024. Randomized controlled trials (RCTs) comparing liraglutide to placebo and reporting body composition outcomes were included.</div></div><div><h3>Results</h3><div>Data from 15 studies involving 960 participants were analyzed. Liraglutide consistently demonstrated significant reductions in total weight, fat mass, and visceral adipose tissue (VAT) compared to placebo across the included studies. VAT reductions ranged from 12.49 % to 23 %, highlighting liraglutide's effectiveness in targeting visceral fat, a key factor in cardiometabolic risk. Fat mass reductions were also substantial and consistent, reinforcing the efficacy of liraglutide in improving overall body composition. In contrast, lean mass outcomes were more variable, with some studies reporting preservation or even gains in lean mass, while others indicated losses.</div></div><div><h3>Conclusions</h3><div>Liraglutide effectively reduces fat mass and VAT, supporting its use in managing obesity and related cardiometabolic risks. However, the inability to accurately calculate lean and fat mass proportions underscores the need for standardized reporting and availability of individual-level data. Future research should prioritize these elements and include muscle function assessments to better evaluate the clinical impacts of GLP-1 receptor agonists on body composition.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 11-18"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.02.001
Zhaoxin Wang , Xiujuan Liu , Lei Sheng , Yuting Xie , Wanyu Feng , Li Yu
Background
High-fat diet (HFD) contributes to obesity and enhances the expression of mature adipocyte markers. However, the effect of HFD on adipocyte hyperplasia remains controversial. This may be due to variations in the duration of HFD. This study aimed to investigate the effects of different durations of HFD on adipocyte hyperplasia and the expression of mature adipocyte-related markers in obese rats.
Methods
We divided 32 Sprague-Dawley rats into four groups: B (standard diet control), H1 (HFD for four weeks), H2 (HFD for eight weeks), and H3 (HFD for 12 weeks). We evaluated the morphological changes in epididymal fat cells, measured serum inflammatory markers using enzyme-linked immunosorbent assay (ELISA) kits, and quantified adipocyte hyperplasia and maturation markers using western blotting.
Results
We observed progressive increases in body weight, epididymal fat weight, serum leptin, TNF-α, IL-6, irisin, PPARγ, adiponectin, and FNDC5 protein expression over 8 weeks of HFD. 12 weeks of HFD intervention resulted in significant decreases in irisin, PPARγ, adiponectin, and FNDC5. Concurrently, the expression of perilipin A and ATGL declined with prolonged HFD.
Conclusions
Our results suggest that the duration of HFD significantly affects adipocyte ability to undergo hyperplasia in the epididymis of obese rats. Specifically, 4 weeks of HFD did not change the capacity for adipocyte hyperplasia, while 8 weeks of the diet enhanced this capacity. Interestingly, a longer diet duration (12 weeks) led to a decrease in adipocyte hyperplasia.
{"title":"Effects of duration of high-fat diet on adipocyte hyperplasia in rat epididymis","authors":"Zhaoxin Wang , Xiujuan Liu , Lei Sheng , Yuting Xie , Wanyu Feng , Li Yu","doi":"10.1016/j.orcp.2025.02.001","DOIUrl":"10.1016/j.orcp.2025.02.001","url":null,"abstract":"<div><h3>Background</h3><div>High-fat diet (HFD) contributes to obesity and enhances the expression of mature adipocyte markers. However, the effect of HFD on adipocyte hyperplasia remains controversial. This may be due to variations in the duration of HFD. This study aimed to investigate the effects of different durations of HFD on adipocyte hyperplasia and the expression of mature adipocyte-related markers in obese rats.</div></div><div><h3>Methods</h3><div>We divided 32 Sprague-Dawley rats into four groups: B (standard diet control), H1 (HFD for four weeks), H2 (HFD for eight weeks), and H3 (HFD for 12 weeks). We evaluated the morphological changes in epididymal fat cells, measured serum inflammatory markers using enzyme-linked immunosorbent assay (ELISA) kits, and quantified adipocyte hyperplasia and maturation markers using western blotting.</div></div><div><h3>Results</h3><div>We observed progressive increases in body weight, epididymal fat weight, serum leptin, TNF-α, IL-6, irisin, PPARγ, adiponectin, and FNDC5 protein expression over 8 weeks of HFD. 12 weeks of HFD intervention resulted in significant decreases in irisin, PPARγ, adiponectin, and FNDC5. Concurrently, the expression of perilipin A and ATGL declined with prolonged HFD.</div></div><div><h3>Conclusions</h3><div>Our results suggest that the duration of HFD significantly affects adipocyte ability to undergo hyperplasia in the epididymis of obese rats. Specifically, 4 weeks of HFD did not change the capacity for adipocyte hyperplasia, while 8 weeks of the diet enhanced this capacity. Interestingly, a longer diet duration (12 weeks) led to a decrease in adipocyte hyperplasia.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 54-62"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.02.004
Fabian Stoll , Tobias Kantowski , Jonas Laaser , Ulrike Kloiber , Gabriel Plitzko , Oliver Mann , Jens Aberle , Anne Lautenbach
Introduction
Insufficient weight loss (IWL) or weight regain (WR) after metabolic bariatric surgery remains a challenge in obesity management. Therefore, this study aimed to retrospectively evaluate the impact of adjunctive tirzepatide therapy over 6 months following sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).
Methods
Post-bariatric patients without type 2 diabetes with IWL or WR (n = 21) were analyzed. Key outcomes included changes in weight, BMI, waist circumference, body composition, basal metabolism, metabolic markers, and inflammatory markers. Subgroup analyses assessed differences based on sex, surgery type, and classification as IWL or WR. Linear regression was performed to identify predictors of weight loss outcomes.
Results
At 6 months, mean total weight loss was 12.0 % ± 3.4 % (p < 0.001), with significant reductions in BMI, waist circumference, body fat percentage, and HbA1c. Basal metabolism declined proportionally with weight loss. Weight loss ≥ 5 % occurred in 100.0 % of patients, ≥ 10 % in 76.5 %, and ≥ 15 % in 23.5 %. Basal metabolism differences between RYGB and SG patients converged by 6 months. Male and female patients showed comparable weight loss and metabolic adaptation. IWL patients experienced less fat-free mass loss at 3 months compared to WR (p < 0.05). Baseline BMI nadir, prior weight regain, body composition, and chronic inflammation were significant predictors of weight loss outcomes.
Discussion
Tirzepatide treatment significantly enhances weight loss and metabolic health in post-bariatric patients, regardless of surgery type or sex. Differences in fat-free mass loss highlight the need for tailored interventions in IWL and WR groups. Baseline factors, including inflammation and body composition, may help predict treatment success.
{"title":"Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition","authors":"Fabian Stoll , Tobias Kantowski , Jonas Laaser , Ulrike Kloiber , Gabriel Plitzko , Oliver Mann , Jens Aberle , Anne Lautenbach","doi":"10.1016/j.orcp.2025.02.004","DOIUrl":"10.1016/j.orcp.2025.02.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Insufficient weight loss (IWL) or weight regain (WR) after metabolic bariatric surgery remains a challenge in obesity management. Therefore, this study aimed to retrospectively evaluate the impact of adjunctive tirzepatide therapy over 6 months following sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).</div></div><div><h3>Methods</h3><div>Post-bariatric patients without type 2 diabetes with IWL or WR (n = 21) were analyzed. Key outcomes included changes in weight, BMI, waist circumference, body composition, basal metabolism, metabolic markers, and inflammatory markers. Subgroup analyses assessed differences based on sex, surgery type, and classification as IWL or WR. Linear regression was performed to identify predictors of weight loss outcomes.</div></div><div><h3>Results</h3><div>At 6 months, mean total weight loss was 12.0 % ± 3.4 % (p < 0.001), with significant reductions in BMI, waist circumference, body fat percentage, and HbA1c. Basal metabolism declined proportionally with weight loss. Weight loss ≥ 5 % occurred in 100.0 % of patients, ≥ 10 % in 76.5 %, and ≥ 15 % in 23.5 %. Basal metabolism differences between RYGB and SG patients converged by 6 months. Male and female patients showed comparable weight loss and metabolic adaptation. IWL patients experienced less fat-free mass loss at 3 months compared to WR (p < 0.05). Baseline BMI nadir, prior weight regain, body composition, and chronic inflammation were significant predictors of weight loss outcomes.</div></div><div><h3>Discussion</h3><div>Tirzepatide treatment significantly enhances weight loss and metabolic health in post-bariatric patients, regardless of surgery type or sex. Differences in fat-free mass loss highlight the need for tailored interventions in IWL and WR groups. Baseline factors, including inflammation and body composition, may help predict treatment success.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 63-69"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.01.006
Małgorzata Jeziorek , Gabriela Kania , Ivana Stanimirova , Klaudia Konikowska , Andrzej Szuba , Angelika Chachaj
Obesity is a leading cause of cardiovascular diseases. There are significant and mutual associations between lymphatic dysfunction and obesity. This case-control study aimed to compare nutrient intake, depressive symptoms, and Eysenck’s personality traits in patients with lower extremity lymphedema and overweight/obesity (n = 34) in comparison to patients with lifestyle-induced overweight/obesity (n = 30) and patients with normal body weight (n = 30). The study groups were evaluated using the Food Frequency Questionnaire (FFQ), Beck Depression Inventory-II, and Eysenck Personality Questionnaire-Revised (EPQ-R). Surprisingly, the study groups did not differ in any item in the FFQ, including total daily energy value and total intake of macronutrients, vitamins, or minerals. The group with lymphedema and overweight/obesity had higher scores on the depression scale, and the groups with lymphedema and overweight/obesity and lifestyle-induced overweight/obesity differed from the control group in Eysenck’s psychoticism score; however, in all study groups, the scores of this trait were within the normal range. In conclusion, our study suggests that when FFQ is used, the problem of under-reporting of usual dietary intake among patients with lower extremity lymphedema and overweight/obesity, and lifestyle-induced overweight/obesity should be considered.
{"title":"Insights into diet, psychological distress, and personality traits among patients with lower-extremity lymphedema and overweight/obesity in comparison to patients with lifestyle-induced overweight/obesity and patients with normal body weight","authors":"Małgorzata Jeziorek , Gabriela Kania , Ivana Stanimirova , Klaudia Konikowska , Andrzej Szuba , Angelika Chachaj","doi":"10.1016/j.orcp.2025.01.006","DOIUrl":"10.1016/j.orcp.2025.01.006","url":null,"abstract":"<div><div>Obesity is a leading cause of cardiovascular diseases. There are significant and mutual associations between lymphatic dysfunction and obesity. This case-control study aimed to compare nutrient intake, depressive symptoms, and Eysenck’s personality traits in patients with lower extremity lymphedema and overweight/obesity (n = 34) in comparison to patients with lifestyle-induced overweight/obesity (n = 30) and patients with normal body weight (n = 30). The study groups were evaluated using the Food Frequency Questionnaire (FFQ), Beck Depression Inventory-II, and Eysenck Personality Questionnaire-Revised (EPQ-R). Surprisingly, the study groups did not differ in any item in the FFQ, including total daily energy value and total intake of macronutrients, vitamins, or minerals. The group with lymphedema and overweight/obesity had higher scores on the depression scale, and the groups with lymphedema and overweight/obesity and lifestyle-induced overweight/obesity differed from the control group in Eysenck’s psychoticism score; however, in all study groups, the scores of this trait were within the normal range. In conclusion, our study suggests that when FFQ is used, the problem of under-reporting of usual dietary intake among patients with lower extremity lymphedema and overweight/obesity, and lifestyle-induced overweight/obesity should be considered.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 48-53"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.01.011
Marina Azab , Luca Pasina
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used for type 2 diabetes (T2D) and approved for obesity by the FDA in 2022 and in Europe in 2023. Its increasing use has raised concerns about access for T2D patients and potential adverse events (AE), such as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). This study investigates the association between semaglutide and these AE using the FDA Adverse Event Reporting System (FAERS). We conducted a disproportionality analysis using FAERS data. AE were identified using MedDRA Preferred Terms (PTs) and related terms. OpenVigil 2.1 was used for data extraction and analysis. This system is a spontaneous safety surveillance database for drugs. The participants are patients who reported AE related to GLP-1 receptor agonists in the FAERS database from January 1, 2004, to September 30, 2024. Reporting Odds Ratios (ROR) and Proportional Reporting Ratios (PRR) were calculated to assess the association between GLP-1 receptor agonists and the AE. Semaglutide showed a significant ROR and PRR for NAION, suggesting a stronger association compared to other GLP-1 receptor agonists. The findings suggest a disproportionate reporting signal for semaglutide and NAION. The mechanisms behind these associations are not fully understood but may involve effects on the hypothalamus and vascular health. Further research is necessary to confirm these findings ensure the safe use of semaglutide, given the potential risk associated with this rare but severe adverse event.
{"title":"Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system – A disproportionality analysis","authors":"Marina Azab , Luca Pasina","doi":"10.1016/j.orcp.2025.01.011","DOIUrl":"10.1016/j.orcp.2025.01.011","url":null,"abstract":"<div><div>Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used for type 2 diabetes (T2D) and approved for obesity by the FDA in 2022 and in Europe in 2023. Its increasing use has raised concerns about access for T2D patients and potential adverse events (AE), such as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). This study investigates the association between semaglutide and these AE using the FDA Adverse Event Reporting System (FAERS). We conducted a disproportionality analysis using FAERS data. AE were identified using MedDRA Preferred Terms (PTs) and related terms. OpenVigil 2.1 was used for data extraction and analysis. This system is a spontaneous safety surveillance database for drugs. The participants are patients who reported AE related to GLP-1 receptor agonists in the FAERS database from January 1, 2004, to September 30, 2024. Reporting Odds Ratios (ROR) and Proportional Reporting Ratios (PRR) were calculated to assess the association between GLP-1 receptor agonists and the AE. Semaglutide showed a significant ROR and PRR for NAION, suggesting a stronger association compared to other GLP-1 receptor agonists. The findings suggest a disproportionate reporting signal for semaglutide and NAION. The mechanisms behind these associations are not fully understood but may involve effects on the hypothalamus and vascular health. Further research is necessary to confirm these findings ensure the safe use of semaglutide, given the potential risk associated with this rare but severe adverse event.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 77-79"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.01.007
Yejin Kim , Jennifer L. Kuk , Kyung Hee Park , SoJung Lee
Background
Waist circumference (WC) has been recognized as a simple anthropometric measure of abdominal obesity and associated health risk. We compared WC values at five measurement sites, and examined whether measurement sites influence the relationships between WC and cardiometabolic risk in Korean adults.
Methods
In this cross-sectional study, participants included 180 men and 176 women (age: 30–60 years, BMI: 18.5–30.0 kg/m2) who underwent a regular health examination between 2021 and 2022. WC was measured at the following sites; lowest rib, superior border of the iliac crest, midpoint between the lowest rib and the iliac crest, umbilicus, and narrowest waist. Fasting glucose and lipids, and resting blood pressure were measured after a 10-hour overnight fast. Cardiometabolic risk factors were defined using the modified National Cholesterol Education Program Adult Treatment Panel-III.
Results
All WC measures at five sites were highly correlated (P < 0.01) with each other in men (r = 0.933–0.995) and women (r = 0.893–0.990). Differences in absolute mean WC values existed in both men and women. The prevalence of abdominal obesity (men: 17.2 %-34.4 %, women: 5.7 %-40.9 %) and metabolic syndrome (men: 30.6 %-38.9 % women: 13.6 %-22.2 %) varied depending on the measurement site. All five WC sites were similarly associated (P < 0.05) with an increased odd ratio for elevated glucose, elevated triglycerides, low HDL cholesterol and cardiometabolic risk clustering in men, and elevated blood pressure and cardiometabolic risk clustering in women.
Conclusion
Although the differences in absolute WC values existed, the associations between WC at each site and cardiometabolic risk were similar in Korean adults.
{"title":"Influence of waist circumference measurement site on the cardiometabolic risk factors in Korean adults","authors":"Yejin Kim , Jennifer L. Kuk , Kyung Hee Park , SoJung Lee","doi":"10.1016/j.orcp.2025.01.007","DOIUrl":"10.1016/j.orcp.2025.01.007","url":null,"abstract":"<div><h3>Background</h3><div>Waist circumference (WC) has been recognized as a simple anthropometric measure of abdominal obesity and associated health risk. We compared WC values at five measurement sites, and examined whether measurement sites influence the relationships between WC and cardiometabolic risk in Korean adults.</div></div><div><h3>Methods</h3><div>In this cross-sectional study, participants included 180 men and 176 women (age: 30–60 years, BMI: 18.5–30.0 kg/m<sup>2</sup>) who underwent a regular health examination between 2021 and 2022. WC was measured at the following sites; lowest rib, superior border of the iliac crest, midpoint between the lowest rib and the iliac crest, umbilicus, and narrowest waist. Fasting glucose and lipids, and resting blood pressure were measured after a 10-hour overnight fast. Cardiometabolic risk factors were defined using the modified National Cholesterol Education Program Adult Treatment Panel-III.</div></div><div><h3>Results</h3><div>All WC measures at five sites were highly correlated (<em>P</em> < 0.01) with each other in men (<em>r</em> = 0.933–0.995) and women (<em>r</em> = 0.893–0.990). Differences in absolute mean WC values existed in both men and women. The prevalence of abdominal obesity (men: 17.2 %-34.4 %, women: 5.7 %-40.9 %) and metabolic syndrome (men: 30.6 %-38.9 % women: 13.6 %-22.2 %) varied depending on the measurement site. All five WC sites were similarly associated (<em>P</em> < 0.05) with an increased odd ratio for elevated glucose, elevated triglycerides, low HDL cholesterol and cardiometabolic risk clustering in men, and elevated blood pressure and cardiometabolic risk clustering in women.</div></div><div><h3>Conclusion</h3><div>Although the differences in absolute WC values existed, the associations between WC at each site and cardiometabolic risk were similar in Korean adults.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 28-33"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.orcp.2025.01.005
Ana Marta Pereira , Sofia S. Pereira , Mariana P. Monteiro , Marta Guimarães
Background
Conversional surgery following sleeve gastrectomy (SG) is required in about 20 % of patients due to suboptimal outcomes. Single anastomosis duodenoileal bypass (SADI) has emerged as an option for such cases, though long-term outcomes remain unclear. This review analyzed available data on SADI as a conversional or second-stage procedure after SG.
Methods
A systematic search across PubMed, Web of Science, and Scopus included studies on adult patients who underwent SADI as a conversional or second-stage surgery following SG, with a minimum of 12 months’ follow-up up to July 2024.
Results
Nineteen studies involving 867 patients examined weight loss, comorbidity resolution, postoperative complications, and nutritional deficiencies. Results showed a total weight loss (TWL) of 24 % in the first year post-revision, with a trend toward weight stabilization or regain over two years. Maximum TWL (27 %) occurred at 24 months, decreasing to 24 % at 60 months. Average follow-up of 27 months showed remission rates for type 2 diabetes, hypertension, and dyslipidemia at 68 %, 53 %, and 37 %, respectively. Short-term morbidity within 30 days was 8 %, including a 5 % rate of anastomotic leaks or fistulas and a 5 % reoperation rate. Overall mortality was 2 %.
Conclusion
In conclusion, SADI shows promise as a safe and effective mid-term conversional surgery after SG with suboptimal results. However, further studies are needed to confirm its long-term safety and effectiveness.
{"title":"Is single anastomosis duodenoileal bypass (SADI) an effective option for conversional surgery following sleeve gastrectomy? A comprehensive review and revised scope of current literature","authors":"Ana Marta Pereira , Sofia S. Pereira , Mariana P. Monteiro , Marta Guimarães","doi":"10.1016/j.orcp.2025.01.005","DOIUrl":"10.1016/j.orcp.2025.01.005","url":null,"abstract":"<div><h3>Background</h3><div>Conversional surgery following sleeve gastrectomy (SG) is required in about 20 % of patients due to suboptimal outcomes. Single anastomosis duodenoileal bypass (SADI) has emerged as an option for such cases, though long-term outcomes remain unclear. This review analyzed available data on SADI as a conversional or second-stage procedure after SG.</div></div><div><h3>Methods</h3><div>A systematic search across PubMed, Web of Science, and Scopus included studies on adult patients who underwent SADI as a conversional or second-stage surgery following SG, with a minimum of 12 months’ follow-up up to July 2024.</div></div><div><h3>Results</h3><div>Nineteen studies involving 867 patients examined weight loss, comorbidity resolution, postoperative complications, and nutritional deficiencies. Results showed a total weight loss (TWL) of 24 % in the first year post-revision, with a trend toward weight stabilization or regain over two years. Maximum TWL (27 %) occurred at 24 months, decreasing to 24 % at 60 months. Average follow-up of 27 months showed remission rates for type 2 diabetes, hypertension, and dyslipidemia at 68 %, 53 %, and 37 %, respectively. Short-term morbidity within 30 days was 8 %, including a 5 % rate of anastomotic leaks or fistulas and a 5 % reoperation rate. Overall mortality was 2 %.</div></div><div><h3>Conclusion</h3><div>In conclusion, SADI shows promise as a safe and effective mid-term conversional surgery after SG with suboptimal results. However, further studies are needed to confirm its long-term safety and effectiveness.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 1-10"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号